Buchumschlag

Agalsidase alfa and kidney dysfunction in Fabry disease

In male patients with Fabry disease, an X-linked disorder of glycosphingolipid metabolism caused by deficient activity of the lysosomal enzyme α-galactosidase A, kidney dysfunction becomes apparent by the third decade of life and invariably progresses to ESRD without treatment. Here, we summarize th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: West, Michael (VerfasserIn) , Ries, Markus (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 2009
In: Journal of the American Society of Nephrology
Year: 2009, Jahrgang: 20, Heft: 5, Pages: 1132-1139
ISSN:1533-3450
DOI:10.1681/ASN.2008080870
Online-Zugang:Verlag, Volltext: https://doi.org/10.1681/ASN.2008080870
Verlag, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678048/
Volltext
Verfasserangaben:Michael West, Kathy Nicholls, Atul Mehta, Joe T.R. Clarke, Robert Steiner, Michael Beck, Bruce A. Barshop, William Rhead, Robert Mensah, Markus Ries, Raphael Schiffmann

MARC

LEADER 00000caa a2200000 c 4500
001 1665086580
003 DE-627
005 20230426130921.0
007 cr uuu---uuuuu
008 190509s2009 xx |||||o 00| ||eng c
024 7 |a 10.1681/ASN.2008080870  |2 doi 
035 |a (DE-627)1665086580 
035 |a (DE-599)KXP1665086580 
035 |a (OCoLC)1341212768 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a West, Michael  |e VerfasserIn  |0 (DE-588)1185724842  |0 (DE-627)1665086750  |4 aut 
245 1 0 |a Agalsidase alfa and kidney dysfunction in Fabry disease  |c Michael West, Kathy Nicholls, Atul Mehta, Joe T.R. Clarke, Robert Steiner, Michael Beck, Bruce A. Barshop, William Rhead, Robert Mensah, Markus Ries, Raphael Schiffmann 
264 1 |c May 2009 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 09.05.2019 
520 |a In male patients with Fabry disease, an X-linked disorder of glycosphingolipid metabolism caused by deficient activity of the lysosomal enzyme α-galactosidase A, kidney dysfunction becomes apparent by the third decade of life and invariably progresses to ESRD without treatment. Here, we summarize the effects of agalsidase alfa on kidney function from three prospective, randomized, placebo-controlled trials and their open-label extension studies involving 108 adult male patients. The mean baseline GFR among 54 nonhyperfiltrating patients (measured GFR <135 ml/min per 1.73 m2) treated with placebo was 85.4 ± 29.6 ml/min per 1.73 m2; during 6 mo of placebo, the mean annualized rate of change in GFR was −7.0 ± 32.9 ml/min per 1.73 m2. Among 85 nonhyperfiltrating patients treated with agalsidase alfa, the annualized rate of change was −2.9 ± 8.7 ml/min per 1.73 m2. Treatment with agalsidase alfa did not affect proteinuria. Multivariate analysis revealed that GFR and proteinuria category (<1 or ≥1 g/d) at baseline significantly predicted the rate of decline of GFR during treatment. This summary represents the largest group of male patients who had Fabry disease and for whom the effects of enzyme replacement therapy on kidney function have been studied. These data suggest that agalsidase alfa may stabilize kidney function in these patients. 
700 1 |a Ries, Markus  |d 1971-  |e VerfasserIn  |0 (DE-588)136385338  |0 (DE-627)582068479  |0 (DE-576)300993358  |4 aut 
773 0 8 |i Enthalten in  |a American Society of Nephrology  |t Journal of the American Society of Nephrology  |d Washington, DC : American Society of Nephrology, 1990  |g 20(2009), 5, Seite 1132-1139  |h Online-Ressource  |w (DE-627)324616481  |w (DE-600)2029124-3  |w (DE-576)094113769  |x 1533-3450  |7 nnas 
773 1 8 |g volume:20  |g year:2009  |g number:5  |g pages:1132-1139  |g extent:8  |a Agalsidase alfa and kidney dysfunction in Fabry disease 
856 4 0 |u https://doi.org/10.1681/ASN.2008080870  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678048/  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190509 
993 |a Article 
994 |a 2009 
998 |g 136385338  |a Ries, Markus  |m 136385338:Ries, Markus  |p 10 
999 |a KXP-PPN1665086580  |e 3472588497 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1665086580","id":{"doi":["10.1681/ASN.2008080870"],"eki":["1665086580"]},"title":[{"title":"Agalsidase alfa and kidney dysfunction in Fabry disease","title_sort":"Agalsidase alfa and kidney dysfunction in Fabry disease"}],"note":["Gesehen am 09.05.2019"],"physDesc":[{"extent":"8 S."}],"person":[{"given":"Michael","role":"aut","display":"West, Michael","roleDisplay":"VerfasserIn","family":"West"},{"given":"Markus","role":"aut","display":"Ries, Markus","family":"Ries","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Michael West, Kathy Nicholls, Atul Mehta, Joe T.R. Clarke, Robert Steiner, Michael Beck, Bruce A. Barshop, William Rhead, Robert Mensah, Markus Ries, Raphael Schiffmann"]},"relHost":[{"recId":"324616481","pubHistory":["1.1990 -"],"titleAlt":[{"title":"JASN"}],"corporate":[{"roleDisplay":"VerfasserIn","display":"American Society of Nephrology","role":"aut"}],"id":{"zdb":["2029124-3"],"eki":["324616481"],"issn":["1533-3450"]},"title":[{"subtitle":"JASN","title":"Journal of the American Society of Nephrology","title_sort":"Journal of the American Society of Nephrology"}],"disp":"American Society of NephrologyJournal of the American Society of Nephrology","note":["Gesehen am 19.08.24"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"American Society of Nephrology ; Ovid","dateIssuedKey":"1990","publisherPlace":"Washington, DC ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1990-"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"8","year":"2009","pages":"1132-1139","text":"20(2009), 5, Seite 1132-1139","volume":"20","issue":"5"}}],"origin":[{"dateIssuedDisp":"May 2009","dateIssuedKey":"2009"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"]} 
SRT |a WESTMICHAEAGALSIDASE2009 

Ähnliche Einträge